This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Inclusion Criteria: 1. Age ≥ 2 years 2. Primary Diagnosis: Myelodysplastic Syndrome (presenting with low or intermediate-1 IPSS risk), thalassemia or rare anemias patients (anemia Diamond-Blackfan, Fanconi's anemia, Sideroblastic anemia, Red cell aplasia) 3. ECOG Performance Status ≤ 2 4. Transfusion overload confirmed with ferritin level \>1000 µg/l. 5. No severe concomitant uncontrolled disease (uncontrolled diabetes mellitus, heart failure, renal failure). 6. Serum creatine level \> ULN 7. No proteinuria 8. Liver enzymes level \< 5 ULN. 9. No pregnancy or lactation 10. Signed informed consent by adults. In case inclusion of children under 18 years old, the informed consent should be signed by parents. Exclusion Criteria: 1. Age \< 2 years 2. No iron overload (Ferritin level \<1000 µg/l). 3. Primary iron overload (hereditary hemochromatosis) 4. Severe concomitant disease (uncontrolled diabetes mellitus, heart failure, renal failure) 5. Elevated serum creatinine \> ULN or/and proteinuria 6. Liver enzymes level \>5 ULN. 7. Pregnancy or lactation. Other protocol-defined inclusion/exclusion criteria may apply